Unmet need for primary prevention in individuals with hypertriglyceridaemia not eligible for statin therapy according to European Society of Cardiology/European Atherosclerosis Society guidelines: a contemporary population-based study

Christian M Madsen; Anette Varbo; Børge G Nordestgaard

doi:10.1093/eurheartj/ehx659

Unmet need for primary prevention in individuals with hypertriglyceridaemia not eligible for statin therapy according to European Society of Cardiology/European Atherosclerosis Society guidelines: a contemporary population-based study

Christian M Madsen, Anette Varbo, Børge G Nordestgaard

Institut for Klinisk Medicin

21 Citationer (Scopus)

Abstract

Aims: To identify individuals at high risk of atherosclerotic cardiovascular disease (ASCVD), who are not definite statin eligible according to the 2016 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines, based on high concentrations of plasma triglycerides. Methods From the Copenhagen General Population Study (2003-2015) 58 547 individuals aged 40-65 and free of ASCVD, and results diabetes, and statin use at baseline were included. Of these, 14% were definite statin eligible, 7% were not eligible and had triglycerides ≥3.0mmol/L (264mg/dL), and 79% were not statin eligible and had triglycerides <3.0mmol/L (264mg/dL). During 456 057 person-years of follow-up, 1770 individuals experienced a major adverse cardiovascular event (MACE) and 734 experienced a myocardial infarction (MI). The cumulative incidences of MACE at age 70 were 8.1% (95% confidence interval 7.3-8.9%) and 14.6% (12.6-16.8%) in statin non-eligible individuals with triglycerides <3.0mmol/L (264mg/dL) and ≥3.0mmol/L (264mg/dL), and 16.5% (14.0-19.3%) in statin eligible individuals. Corresponding cumulative incidences of MI were 3.0% (2.7-3.3%), 7.8% (6.4-9.5%), and 7.1% (5.9-8.4%), respectively. The estimated 10-year risks of MACE were 2.8% (2.6-3.0%) and 5.7% (4.9-6.6%) in statin non-eligible individuals with triglycerides <3.0mmol/L (264mg/dL) and ≥3.0mmol/L (264mg/dL), and 7.6% (6.9-8.3%) in statin eligible individuals; the median age in these three groups were 51, 51, and 60years, respectively. Corresponding risks of MI were 1.0% (0.9-1.1%), 3.0% (2.4-3.7%), and 3.3% (2.8-3.7%), respectively. Conclusion: Statin non-eligible individuals with triglycerides ≥3.0mmol/L (264mg/dL) had risk of ASCVD similar to statin eligible individuals, defined according to the 2016 ESC/EAS guidelines. This illustrates an unmet need for primary prevention, calling for expansion of guidelines on statin eligibility, and the potential for placebo-controlled randomized clinical trials in individuals with hypertriglyceridaemia.

Originalsprog	Engelsk
Tidsskrift	European Heart Journal
Vol/bind	39
Udgave nummer	7
Sider (fra-til)	610-619
Antal sider	10
ISSN	0195-668X
DOI	https://doi.org/10.1093/eurheartj/ehx659
Status	Udgivet - 14 feb. 2018

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.1093/eurheartj/ehx659

ehx659.pdfForlagets udgivne version, 587 KB

Fingeraftryk

Dyk ned i forskningsemnerne om 'Unmet need for primary prevention in individuals with hypertriglyceridaemia not eligible for statin therapy according to European Society of Cardiology/European Atherosclerosis Society guidelines: a contemporary population-based study'. Sammen danner de et unikt fingeraftryk.

Citationsformater

Madsen, C. M., Varbo, A., & Nordestgaard, B. G. (2018). Unmet need for primary prevention in individuals with hypertriglyceridaemia not eligible for statin therapy according to European Society of Cardiology/European Atherosclerosis Society guidelines: a contemporary population-based study. European Heart Journal, 39(7), 610-619. https://doi.org/10.1093/eurheartj/ehx659

Unmet need for primary prevention in individuals with hypertriglyceridaemia not eligible for statin therapy according to European Society of Cardiology/European Atherosclerosis Society guidelines : a contemporary population-based study. / Madsen, Christian M; Varbo, Anette; Nordestgaard, Børge G.

I: European Heart Journal, Bind 39, Nr. 7, 14.02.2018, s. 610-619.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Madsen, CM, Varbo, A & Nordestgaard, BG 2018, 'Unmet need for primary prevention in individuals with hypertriglyceridaemia not eligible for statin therapy according to European Society of Cardiology/European Atherosclerosis Society guidelines: a contemporary population-based study', European Heart Journal, bind 39, nr. 7, s. 610-619. https://doi.org/10.1093/eurheartj/ehx659

@article{3597aee562ed41f39732d8a17a82543f,

title = "Unmet need for primary prevention in individuals with hypertriglyceridaemia not eligible for statin therapy according to European Society of Cardiology/European Atherosclerosis Society guidelines: a contemporary population-based study",

abstract = "Aims: To identify individuals at high risk of atherosclerotic cardiovascular disease (ASCVD), who are not definite statin eligible according to the 2016 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines, based on high concentrations of plasma triglycerides. Methods From the Copenhagen General Population Study (2003-2015) 58 547 individuals aged 40-65 and free of ASCVD, and results diabetes, and statin use at baseline were included. Of these, 14% were definite statin eligible, 7% were not eligible and had triglycerides ≥3.0mmol/L (264mg/dL), and 79% were not statin eligible and had triglycerides <3.0mmol/L (264mg/dL). During 456 057 person-years of follow-up, 1770 individuals experienced a major adverse cardiovascular event (MACE) and 734 experienced a myocardial infarction (MI). The cumulative incidences of MACE at age 70 were 8.1% (95% confidence interval 7.3-8.9%) and 14.6% (12.6-16.8%) in statin non-eligible individuals with triglycerides <3.0mmol/L (264mg/dL) and ≥3.0mmol/L (264mg/dL), and 16.5% (14.0-19.3%) in statin eligible individuals. Corresponding cumulative incidences of MI were 3.0% (2.7-3.3%), 7.8% (6.4-9.5%), and 7.1% (5.9-8.4%), respectively. The estimated 10-year risks of MACE were 2.8% (2.6-3.0%) and 5.7% (4.9-6.6%) in statin non-eligible individuals with triglycerides <3.0mmol/L (264mg/dL) and ≥3.0mmol/L (264mg/dL), and 7.6% (6.9-8.3%) in statin eligible individuals; the median age in these three groups were 51, 51, and 60years, respectively. Corresponding risks of MI were 1.0% (0.9-1.1%), 3.0% (2.4-3.7%), and 3.3% (2.8-3.7%), respectively. Conclusion: Statin non-eligible individuals with triglycerides ≥3.0mmol/L (264mg/dL) had risk of ASCVD similar to statin eligible individuals, defined according to the 2016 ESC/EAS guidelines. This illustrates an unmet need for primary prevention, calling for expansion of guidelines on statin eligibility, and the potential for placebo-controlled randomized clinical trials in individuals with hypertriglyceridaemia.",

author = "Madsen, {Christian M} and Anette Varbo and Nordestgaard, {B{\o}rge G}",

year = "2018",

month = feb,

day = "14",

doi = "10.1093/eurheartj/ehx659",

language = "English",

volume = "39",

pages = "610--619",

journal = "European Heart Journal",

issn = "0195-668X",

publisher = "Oxford University Press",

number = "7",

}

TY - JOUR

T1 - Unmet need for primary prevention in individuals with hypertriglyceridaemia not eligible for statin therapy according to European Society of Cardiology/European Atherosclerosis Society guidelines

T2 - a contemporary population-based study

AU - Madsen, Christian M

AU - Varbo, Anette

AU - Nordestgaard, Børge G

PY - 2018/2/14

Y1 - 2018/2/14

N2 - Aims: To identify individuals at high risk of atherosclerotic cardiovascular disease (ASCVD), who are not definite statin eligible according to the 2016 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines, based on high concentrations of plasma triglycerides. Methods From the Copenhagen General Population Study (2003-2015) 58 547 individuals aged 40-65 and free of ASCVD, and results diabetes, and statin use at baseline were included. Of these, 14% were definite statin eligible, 7% were not eligible and had triglycerides ≥3.0mmol/L (264mg/dL), and 79% were not statin eligible and had triglycerides <3.0mmol/L (264mg/dL). During 456 057 person-years of follow-up, 1770 individuals experienced a major adverse cardiovascular event (MACE) and 734 experienced a myocardial infarction (MI). The cumulative incidences of MACE at age 70 were 8.1% (95% confidence interval 7.3-8.9%) and 14.6% (12.6-16.8%) in statin non-eligible individuals with triglycerides <3.0mmol/L (264mg/dL) and ≥3.0mmol/L (264mg/dL), and 16.5% (14.0-19.3%) in statin eligible individuals. Corresponding cumulative incidences of MI were 3.0% (2.7-3.3%), 7.8% (6.4-9.5%), and 7.1% (5.9-8.4%), respectively. The estimated 10-year risks of MACE were 2.8% (2.6-3.0%) and 5.7% (4.9-6.6%) in statin non-eligible individuals with triglycerides <3.0mmol/L (264mg/dL) and ≥3.0mmol/L (264mg/dL), and 7.6% (6.9-8.3%) in statin eligible individuals; the median age in these three groups were 51, 51, and 60years, respectively. Corresponding risks of MI were 1.0% (0.9-1.1%), 3.0% (2.4-3.7%), and 3.3% (2.8-3.7%), respectively. Conclusion: Statin non-eligible individuals with triglycerides ≥3.0mmol/L (264mg/dL) had risk of ASCVD similar to statin eligible individuals, defined according to the 2016 ESC/EAS guidelines. This illustrates an unmet need for primary prevention, calling for expansion of guidelines on statin eligibility, and the potential for placebo-controlled randomized clinical trials in individuals with hypertriglyceridaemia.

AB - Aims: To identify individuals at high risk of atherosclerotic cardiovascular disease (ASCVD), who are not definite statin eligible according to the 2016 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines, based on high concentrations of plasma triglycerides. Methods From the Copenhagen General Population Study (2003-2015) 58 547 individuals aged 40-65 and free of ASCVD, and results diabetes, and statin use at baseline were included. Of these, 14% were definite statin eligible, 7% were not eligible and had triglycerides ≥3.0mmol/L (264mg/dL), and 79% were not statin eligible and had triglycerides <3.0mmol/L (264mg/dL). During 456 057 person-years of follow-up, 1770 individuals experienced a major adverse cardiovascular event (MACE) and 734 experienced a myocardial infarction (MI). The cumulative incidences of MACE at age 70 were 8.1% (95% confidence interval 7.3-8.9%) and 14.6% (12.6-16.8%) in statin non-eligible individuals with triglycerides <3.0mmol/L (264mg/dL) and ≥3.0mmol/L (264mg/dL), and 16.5% (14.0-19.3%) in statin eligible individuals. Corresponding cumulative incidences of MI were 3.0% (2.7-3.3%), 7.8% (6.4-9.5%), and 7.1% (5.9-8.4%), respectively. The estimated 10-year risks of MACE were 2.8% (2.6-3.0%) and 5.7% (4.9-6.6%) in statin non-eligible individuals with triglycerides <3.0mmol/L (264mg/dL) and ≥3.0mmol/L (264mg/dL), and 7.6% (6.9-8.3%) in statin eligible individuals; the median age in these three groups were 51, 51, and 60years, respectively. Corresponding risks of MI were 1.0% (0.9-1.1%), 3.0% (2.4-3.7%), and 3.3% (2.8-3.7%), respectively. Conclusion: Statin non-eligible individuals with triglycerides ≥3.0mmol/L (264mg/dL) had risk of ASCVD similar to statin eligible individuals, defined according to the 2016 ESC/EAS guidelines. This illustrates an unmet need for primary prevention, calling for expansion of guidelines on statin eligibility, and the potential for placebo-controlled randomized clinical trials in individuals with hypertriglyceridaemia.

U2 - 10.1093/eurheartj/ehx659

DO - 10.1093/eurheartj/ehx659

M3 - Journal article

C2 - 29182745

SN - 0195-668X

VL - 39

SP - 610

EP - 619

JO - European Heart Journal

JF - European Heart Journal

IS - 7

ER -